<DOC>
	<DOCNO>NCT01557647</DOCNO>
	<brief_summary>To evaluate effect inhale treprostinil compare placebo exercise capacity time clinical worsening .</brief_summary>
	<brief_title>Safety Efficacy Inhaled Treprostinil Patients With PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Eligible subject must : Be 18 75 year age Screening ( define date inform consent sign ) , Have diagnosis idiopathic heritable PAH , PAH associate connective tissue disease ( CTD ) , PAH associate repaired congenital systemictopulmonary shunt ( least 1 year since repair ) human immunodeficiency virus ( HIV ) infection , PAH associate appetite suppressant toxin use . Be treatment na√Øve , receive background PAH therapy ( e.g. , phosphodiesterase type5 inhibitor ( PDE5i ) / endothelin receptor antagonist ( ERA ) ) less 1 year prior Screening . Have 6MWD Baseline ( measure mean value two 6MWT separate least 24 hour , 14 day ) 150 500 meter , inclusive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>